...dermatology business through its 2009 acquisition of Stiefel Laboratories Inc. for $2.9 billion (see “GSK to Acquire Stiefel”...

...Roivant Sciences GmbH, Basel, Switzerland GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Dermatology Allison Johnson GSK2894512, WBI-1001 GlaxoSmithKline plc Stiefel Laboratories Inc. Roivant...

...2012 deal with Welichem Biotech Inc. (Burnaby, B.C.). Dermavant declined to provide details. Allison Johnson GSK2894512, WBI-1001 GlaxoSmithKline plc Stiefel Laboratories Inc. Roivant...

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...

...treatments now available to them," noted Jim Lee, VP of global clinical development at the Stiefel Laboratories Inc....

...and Mexico under a June 2010 deal with Basilea Pharmaceutica AG (SIX:BSLN, Basel, Switzerland). GSK’s Stiefel Laboratories Inc....

...the separation of the company's HIV business ViiV Healthcare, its consumer healthcare business and its Stiefel...

...GlaxoSmithKline's Stiefel dermatology business began the double-blind, placebo-controlled, international Phase III OPV116910 trial to compare 20...

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...